Yoko Murayama
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yoko Murayama has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
Kenji Oritani
Yoko Murayama, Shusaku Tsutsui, Department of Gastroenterology and Hepatology, Itami City Hospital, Itami 664-8540, Japan
2 shared publicationsNorio Hayashi
Osaka University
2 shared publicationsShinji Tamura
Minoh City Hospital
2 shared publicationsShusaku Tsutsui
Yoko Murayama, Shusaku Tsutsui, Department of Gastroenterology and Hepatology, Itami City Hospital, Itami 664-8540, Japan
2 shared publicationsTamana Miyazaki
2 shared publicationsYasuhisa Shinomura
Sapporo Medical University
2 shared publications
Latest Publications
- Open Access
- 21 March 2015
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 21 (11) , 3206-3213
Novel CD9-targeted therapies in gastric cancer
There are 33 human tetraspanin proteins, emerging as key players in malignancy, the immune system, fertilization, cellular signaling, adhesion, morphology, motility, proliferation, and tumor invasion. CD9, a member of the tetraspanin family, associates with and influences a variety of cell-surface molecules. Through these interactions, CD9 modifies multiple cellular events, including adhesion, migration, proliferation, and survival. CD9 is therefore considered to play a role in several stages during cancer development. Reduced CD9 expression is generally related to venous vessel invasion and metastasis as well as poor prognosis. We found that treatment of mice bearing human gastric cancer cells with anti-CD9 antibody successfully inhibited tumor progression via antiproliferative, proapoptotic, and antiangiogenic effects, strongly indicating that CD9 is a possible therapeutic target in patients with gastric cancer. Here, we describe the possibility of CD9 manipulation as a novel therapeutic strategy in gastric cancer, which still shows poor prognosis.
- 21 March 2015
- Published by Baishideng Publishing Group Inc. in World Journal of Gastroenterology
- Vol. 21 (11) , 3206-3213
Open AccessNovel CD9-targeted therapies in gastric cancer
There are 33 human tetraspanin proteins, emerging as key players in malignancy, the immune system, fertilization, cellular signaling, adhesion, morphology, motility, proliferation, and tumor invasion. CD9, a member of the tetraspanin family, associates with and influences a variety of cell-surface molecules. Through these interactions, CD9 modifies multiple cellular events, including adhesion, migration, proliferation, and survival. CD9 is therefore considered to play a role in several stages during cancer development. Reduced CD9 expression is generally related to venous vessel invasion and metastasis as well as poor prognosis. We found that treatment of mice bearing human gastric cancer cells with anti-CD9 antibody successfully inhibited tumor progression via antiproliferative, proapoptotic, and antiangiogenic effects, strongly indicating that CD9 is a possible therapeutic target in patients with gastric cancer. Here, we describe the possibility of CD9 manipulation as a novel therapeutic strategy in gastric cancer, which still shows poor prognosis.
- Open Access
- 1 January 2012
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Oncology
- Vol. 4 (5) , 119-124
Greater omentum gastrointestinal stromal tumor withPDGFRA-mutation and hemoperitoneum
Greater omentum gastrointestinal stromal tumor with PDGFRA-mutation and hemoperitoneum
- 1 January 2012
- Published by Baishideng Publishing Group Inc. in World Journal of Gastrointestinal Oncology
- Vol. 4 (5) , 119-124
Open AccessGreater omentum gastrointestinal stromal tumor withPDGFRA-mutation and hemoperitoneum
Greater omentum gastrointestinal stromal tumor with PDGFRA-mutation and hemoperitoneum
- 26 May 2009
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 44 (9) , 889-896
A novel therapeutic strategy with anti-CD9 antibody in gastric cancers
CD9 is a member of the tetraspanins, and has been shown to be involved in a variety of cellular activities such as motility, cell signaling, proliferation, adhesion, and metastasis. However, very little is known about the involvement of CD9 in the process of development of primary tumors. In the present study, we investigated whether anti-CD9 monoclonal antibody (ALB6) has antitumor effects in human gastric cancer cell xenografts.
- 26 May 2009
- Published by Springer Nature in Journal of Gastroenterology
- Vol. 44 (9) , 889-896
A novel therapeutic strategy with anti-CD9 antibody in gastric cancers
CD9 is a member of the tetraspanins, and has been shown to be involved in a variety of cellular activities such as motility, cell signaling, proliferation, adhesion, and metastasis. However, very little is known about the involvement of CD9 in the process of development of primary tumors. In the present study, we investigated whether anti-CD9 monoclonal antibody (ALB6) has antitumor effects in human gastric cancer cell xenografts.
- 22 February 2006
- Published by Wiley in Digestive Endoscopy
- Vol. 18 (2) , 98-104
IS HELICOBACTER PYLORI‐INDUCED ENLARGED FOLD GASTRITIS A HIGH‐RISK FACTOR FOR GASTRIC CARCINOMA?
It is now a generally accepted fact that Helicobacter pylori is an important cause of gastric carcinoma. The International Agency for Research on Cancer classified H. pylori as a group 1 carcinogen. We previously reported that H. pylori‐positive subjects had enlarged folds (fold width = 5 mm); that is, ‘enlarged fold gastritis’. Helicobacter pylori‐induced enlarged fold gastritis is accompanied by a massive infiltration of inflammatory cells, profound production of interleukin‐1β (IL‐1β) and hepatocyte growth factor (HGF), which decrease gastric acid secretion and increase the proliferation rate of the gastric epithelial cells. In addition, there is increased mutagenicity of gastric juice, and mucosal 8‐hydroxydeoxyguanosine (8‐OhdG) levels. Fold width improves and these factors recover to within a normal range with the eradication of H. pylori. The odds ratio for gastric carcinoma and the prevalence of diffuse‐type early gastric carcinoma in the body region increased with an increase in fold width. Therefore, enlarged fold gastritis may be a major risk factor for gastric carcinoma among H. pylori‐infected people. We propose that H. pylori‐infected persons with enlarged fold gastritis are a potential population for the prevention of gastric carcinoma via the use of antibiotics.
- 22 February 2006
- Published by Wiley in Digestive Endoscopy
- Vol. 18 (2) , 98-104
IS HELICOBACTER PYLORI‐INDUCED ENLARGED FOLD GASTRITIS A HIGH‐RISK FACTOR FOR GASTRIC CARCINOMA?
It is now a generally accepted fact that Helicobacter pylori is an important cause of gastric carcinoma. The International Agency for Research on Cancer classified H. pylori as a group 1 carcinogen. We previously reported that H. pylori‐positive subjects had enlarged folds (fold width = 5 mm); that is, ‘enlarged fold gastritis’. Helicobacter pylori‐induced enlarged fold gastritis is accompanied by a massive infiltration of inflammatory cells, profound production of interleukin‐1β (IL‐1β) and hepatocyte growth factor (HGF), which decrease gastric acid secretion and increase the proliferation rate of the gastric epithelial cells. In addition, there is increased mutagenicity of gastric juice, and mucosal 8‐hydroxydeoxyguanosine (8‐OhdG) levels. Fold width improves and these factors recover to within a normal range with the eradication of H. pylori. The odds ratio for gastric carcinoma and the prevalence of diffuse‐type early gastric carcinoma in the body region increased with an increase in fold width. Therefore, enlarged fold gastritis may be a major risk factor for gastric carcinoma among H. pylori‐infected people. We propose that H. pylori‐infected persons with enlarged fold gastritis are a potential population for the prevention of gastric carcinoma via the use of antibiotics.